AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca other Respiratory & Immunology medicines — Emerging Markets YoY CER (%) (%)
Form 6-K / 20-F Product Sales Table
Latest, Q2 2026
-8.0%
Period ended Jun 30, 2026
Change on a year earlier
+17.0 pts
-25.0% in Q2 2025
History
22 quarters
Since Q4 2020
Sources
22
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Respiratory & Immunology medicines — Emerging Markets YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -8.0% | +17.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | -37.0% | -27.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | -6.0% | +32.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | -42.0% | -34.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | -25.0% | -37.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | -10.0% | +17.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | -38.0% | -64.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | -8.0% | +6.0 pts | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 12.0% | +44.0 pts | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | -27.0% | -26.0 pts | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 26.0% | +53.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | -14.0% | +7.0 pts | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | -32.0% | -18.0 pts | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | -1.0% | +3.0 pts | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | -27.0% | -19.0 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q3 2022 | Sep 30, 2022 | -21.0% | -87.0 pts | Form 6-K FY2022Q3 Earnings Release ↗ |
| Q2 2022 | Jun 30, 2022 | -14.0% | – | Form 6-K FY2022Q2 Earnings Release ↗ |
| Q1 2022 | Mar 31, 2022 | -4.0% | -24.0 pts | Form 6-K FY2022Q1 Earnings Release ↗ |
| Q4 2021 | Dec 31, 2021 | -8.0% | +82.0 pts | Form 6-K FY2021Q4 Earnings Release ↗ |
| Q3 2021 | Sep 30, 2021 | 66.0% | – | Form 6-K FY2021Q3 Earnings Release ↗ |
| Q1 2021 | Mar 31, 2021 | 20.0% | – | Form 6-K FY2021Q1 Earnings Release ↗ |
| Q4 2020 | Dec 31, 2020 | -90.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Other Respiratory & Immunology medicines — Emerging Markets YoY CER (%) (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_other_ri_em_cer_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.